FDA Approves Bimzelx (bimekizumab-bkzx) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis

Brussels (Belgium), 18 OCTOBER 2023– UCB, a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved Bimzelx® (bimekizumab-bkzx) for the treatment of moderate to severe plaque...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news